Medication info
Rosucande Tablet 5/8 Milligrams

Rosucande Tablet 5/8 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Daekyung I-Tech Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202107117 · Approved 2021.10.25 · Insurance code 073000770

Summary

Main use
Improvement of hyperlipidemia; treatment of hypertension and heart failure; inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each ingredient, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.
Child dose
Essential hypertension: The safety and efficacy in adolescents and children aged 18 years or younger have not been established. Heart failure: The safety and efficacy in adolescents and children aged 18 years or younger have not been established.

Ingredients

Manufacturer
Daekyung I-Tech Co., Ltd.

Efficacy & effects

Improvement of hyperlipidemia; treatment of hypertension and heart failure; inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular systolic dysfunction
  • hypercholesterolemia
  • familial hypercholesterolemia
  • mixed hyperlipidemia
  • dysbetalipoproteinemia
  • coronary heart disease risk factors
  • stroke risk
  • myocardial infarction risk
View approved original text

This medication is used in patients who require co-administration of the two medications Candesartan Cilexetil and Rosuvastatin. First, Candesartan Cilexetil is used in patients with essential hypertension and heart failure, particularly in those whose left ventricular systolic function is impaired and require additional therapy with ACE inhibitors or have poor tolerance. Rosuvastatin is used as an adjunctive treatment for patients with hypercholesterolemia and mixed hyperlipidemia when diet and exercise are insufficient to control cholesterol levels, helps delay the progression of atherosclerosis, and aids patients with dysbetalipoproteinemia in diet management. Additionally, it helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in patients at high risk for cardiovascular diseases. Together, these two medications are used to manage hypertension and dyslipidemia to improve cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each ingredient, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Child dose

Essential hypertension: The safety and efficacy in adolescents and children aged 18 years or younger have not been established. Heart failure: The safety and efficacy in adolescents and children aged 18 years or younger have not been established.

Precautions

This medication can cause serious harm, especially to the fetus and newborn, during pregnancy; therefore, it must be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with hypersensitivity to this drug or those with liver disease, severe hepatic impairment, renal failure, myopathy, or hereditary angioedema. Women of childbearing potential should take this medication only after being fully aware of the risks to themselves and the fetus, and it is important to use appropriate contraception. Caution should be exercised in certain populations, including the elderly, those with hyperkalemia, patients with hepatic impairment, and those with cardiovascular diseases; blood pressure and kidney function should be monitored regularly. If symptoms such as muscle pain or weakness occur, consult a physician immediately, and in severe cases, the medication may be discontinued. As this drug can affect liver function, periodic liver function tests are necessary before and during treatment. Interactions may occur when co-administered with other antihypertensive or certain medications, so it is essential to inform healthcare providers about all medications being taken. Avoid using this medication during pregnancy or breastfeeding; if breastfeeding, it is recommended to discontinue breastfeeding. Safety in pediatric patients has not been established, so use in children is not recommended. In case of overdose, appropriate treatment is required depending on the symptoms, and caution is necessary as blood pressure drops or dizziness may occur. Caution is needed during driving or operating machinery as temporary dizziness can occur. Keep this medication out of the reach of children and avoid transferring it from its original container to another container.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, indigestion, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, orthostatic dizziness, maculopapular rash, periodontitis, inflammation, foreign body sensation, cataract, musculoskeletal pain, chest discomfort, tooth extraction, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesic syndrome, memory disorders, confusion, severe muscle weakness, oculomotor paralysis, hypotension, hyperkalemia, kidney dysfunction, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, leukopenia, neutropenia, agranulocytosis, malaise, hunger, cold sweat, hand tremors, decreased concentration, seizures, consciousness disturbance, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, exacerbation of hypertension, unstable blood pressure, vertigo, orthostatic vertigo, adrenal insufficiency, syncope, facial flushing, weight gain, facial edema, thirst, decreased libido, forgetfulness, decreased appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, abdominal pain, pancreatitis, low back pain, myalgia, arthralgia, numbness, sensory disturbance, chest discomfort, abdominal distension, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is safe to store it at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the medication's effectiveness.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.